Intelligence

01

What changed between CMS-0057-F and CMS-0062-P?

One is a final rule with compliance dates; the other is a proposal whose comment period closed on June 15, 2026. The answer has to hold that distinction rather than blend the two into a single prior-authorization rule.

Start with Electronic PA and CMS interoperability rules and FHIR APIs and coverage decisions.

02

How do the U.S., Canada, the EU and Australia regulate AI medical devices?

Four regulators, four definitions of when software becomes a device, four post-market regimes. A comparison is only useful if it names what each jurisdiction actually binds.

Start with How the FDA reviews AI-enabled devices and Global AI standards.

03

When does an ambient medical scribe become a regulated medical device?

It turns on therapeutic intended purpose, not on the technology. The same product can be regulated in one jurisdiction and unregulated in another.

Start with Ambient clinical documentation and Generative AI in medical documentation.

04

What AI transparency requirements became operative in California and Europe in August 2026?

Both on August 2, 2026, by design. California reaches content provenance for image, video and audio; EU Article 50 also reaches interaction disclosure and emotion recognition.

Start with California AI Transparency Act record and EU AI Act Article 50 record.

05

What changes for NPDB credentialing queries in December 2026?

One-Time and Continuous Query merge into NPDB Query on December 4, 2026. Continuous enrollments transfer automatically; One-Time users need a transition plan.

Start with Recredentialing and continuous monitoring and Disputing an NPDB report.

06

Do I have to enroll in Medi-Cal to prescribe for a Medi-Cal patient?

Yes, under an individual Type 1 NPI. Medicare enrollment and plan affiliation are not substitutes. What is unsettled is the enforcement date, not the requirement.

Start with Medi-Cal ORP enrollment record and Credentialing, privileging, enrollment, licensing.

07

What can I still comment on before it becomes law?

The CY 2027 Physician Fee Schedule closes September 14, 2026. CMS-0062-P has already closed. A comment window is the narrowest form of influence and the easiest to miss.

Start with Fixed dates and Public participation in regulation.

When I use a generative tool in my documentation, whose disclosure duty is it?

A physician using a generative tool inside documentation or patient communication is a deployer, not a provider, and the Act does not transfer the provider's disclosure duty onto the clinician. What it does change is the evidentiary picture: where a covered provider generates image, video or audio content, a provenance disclosure travels with that content and is discoverable. Generated text carries no marking duty under this Act, so no provenance trail attaches to it here.

Limit on this answer. Nothing in the Act addresses clinical standard of care or malpractice exposure.

Authority: Bus. & Prof. Code ch. 25 (SB 942, 2024, as amended by AB 853, 2025) — California Legislative Information — AB 853 text

Verified August 15, 2026 · standing record: /weekly/2026-08-15/#caita · full entry: 2026 record

Did Europe's delay of the high-risk AI rules delay anything that reaches a clinic?

The high-risk obligations most relevant to clinical devices are deferred to a later date; the transparency layer is not. A European deployment of an ambient scribe or triage chatbot carries a disclosure duty now, independent of whether the system is ultimately classified high-risk.

Limit on this answer. Deferral of the high-risk timetable did not defer Article 50, and no health-sector carve-out applies.

Authority: Regulation (EU) 2024/1689 (AI Act), Article 50 — European Commission — guidelines on Article 50 transparency obligations

Verified August 15, 2026 · standing record: /weekly/2026-08-15/#eu-art50 · full entry: 2026 record

Why would a Medicaid provider-tax rule reach my practice?

This is a financing rule with clinical consequences: provider taxes fund a large share of the non-federal Medicaid share, and a state that loses that revenue adjusts provider rates, eligibility processing, or managed-care capitation — not its statutory obligations. For a physician seeing Medi-Cal patients, the exposure is rate and access pressure two budget cycles out, not a compliance duty.

Limit on this answer. Proposed. The 1 October 2026 statutory date belongs to section 71115, not to this rule; nothing in the proposal binds a state or a provider until a final rule issues.

Authority: CMS-2452-P, 91 FR (2026-14897) — Medicaid Program; Amending the Indirect Hold Harmless Threshold of Health Care-Related Taxes; released 21 July 2026, published 23 July 2026 — Federal Register — CMS-2452-P (23 July 2026) · CMS — CMS-2452-P fact sheet

Verified August 17, 2026 · full entry: 2026 record

Is the two-conversion-factor structure a one-year experiment?

Two conversion factors and an efficiency adjustment carry forward as proposals for a second year, which means the CY 2026 structure is not a one-year experiment. Comment is the only stage at which a physician's operational objection is on the record.

Limit on this answer. No obligation arises until a final rule issues; the 2027 dates in the proposal are not duties.

Authority: CMS-1848-P, 91 FR 43842 — CY 2027 Payment Policies under the Physician Fee Schedule — CMS — CMS-1848-P regulation notice · CMS — CY 2027 PFS fact sheet

Verified August 15, 2026 · standing record: /enforcement/#pfs-2027 · full entry: 2026 record

Is Congress about to put the prior-authorization rules into statute?

This is the legislative track running alongside the CMS interoperability rules. If it passes in this form, the API duties CMS built by rule acquire a statutory floor and a real-time-decision definition that a rule alone can revise.

Limit on this answer. A reported bill is not law. Nothing in it binds any plan today, and committee approval does not schedule a floor vote.

Authority: H.R. 3514, Improving Seniors' Timely Access to Care Act; full-committee markup, 15 July 2026 — House Ways and Means — full-committee markup notice, 15 July 2026 · Congress.gov — H.R. 3514 (119th Congress)

Verified August 16, 2026 · full entry: 2026 record

When a national takedown is announced, what actually happens to a physician's billing?

The administrative half is the part physicians underestimate. A payment suspension or revocation lands before any adjudication and does not wait for a plea, a verdict, or a licensing decision — which is why the CMS numbers, not the defendant count, are the operational risk.

Limit on this answer. Every charge is an allegation. No finding of guilt exists until conviction or plea, and dispositions will be added to this record as they issue rather than replacing it.

Authority: DOJ 2026 National Health Care Fraud Takedown, announced 23 June 2026 — Justice Department — takedown announcement, 23 June 2026 · HHS-OIG — 2026 National Health Care Fraud Takedown case index

Verified August 16, 2026 · full entry: 2026 record

Is it worth appealing a Medicare Advantage denial of post-acute placement?

A 95 percent overturn rate is an argument about initial determinations, not about appeals working. For the discharging physician it means a denial of post-acute placement is worth appealing on the clinical record you already have, and that the delay itself — days in an acute bed — is the harm to document.

Limit on this answer. An audit finding is not an enforcement action and establishes no violation by any named plan. OIG's data cannot separate denials that should never have issued from approvals granted on later documentation.

Authority: OEI-09-24-00331 (skilled nursing facilities) and OEI-09-24-00330 (long-term care hospitals and inpatient rehabilitation facilities), completed 8 June 2026, posted 11 June 2026 — HHS-OIG — MAOs overturned nearly all appealed SNF prior-authorization denials (OEI-09-24-00331) · HHS-OIG — work-plan record for the post-acute prior-authorization reviews

Verified August 16, 2026 · full entry: 2026 record

Do I wait for OHCA's regulations before closing an MSO transaction?

This answers the question the statute left open on 1 January: an MSO transaction closing now is already inside the notice duty, and the interim standard is written notice rather than the full filing package. Waiting for final regulations is not a compliance position.

Limit on this answer. Proposed and, on the record read, not adopted. The definitions and ownership thresholds in the draft may change before adoption, and no compliance date attaches to the draft itself.

Authority: Proposed revisions to the material change transaction and cost-and-market-impact-review regulations (Cal. Code Regs., tit. 22, div. 7, ch. 11.5), text dated May 2026, implementing AB 1415 (Ch. 641, Stats. 2025) — HCAI — Laws & Regulations (OHCA rulemaking to implement AB 1415; comments to 11 June 2026) · HCAI — proposed CMIR regulation text for informal comment, May 2026 · HCAI — AB 1415 frequently asked questions

Verified August 17, 2026 · full entry: 2026 record

Is Great Britain about to diverge from the EU on the devices my colleagues there use?

For a clinician the consequence is downstream and practical: an instrument that changes classification and conformity assessment changes which devices and diagnostic software reach a British clinic, and on what evidence. Healthcare providers were named as consultees, which means the clinical view of a device's real-world performance was solicited at the drafting stage rather than after adoption.

Limit on this answer. A draft statutory instrument. It creates no duty, and adoption requires Parliament; the timetable reported for adoption and entry into force is not part of the notified draft and is not verified here.

Authority: Draft Medical Devices (Amendment) Regulations 2026, notified on the World Trade Organisation portal 8 May 2026; stakeholder impact survey closed 19 June 2026 — GOV.UK — MHRA invites views on proposed changes to medical device regulation

Verified August 17, 2026 · full entry: 2026 record

Why does a European rule about notified bodies matter to what I can order?

Certification delay is the mechanism by which European device rules reach a clinic: a diagnostic or software device that cannot get through a notified body does not arrive. Standardising quotation, timeline and audit practice is aimed at that bottleneck, and it is in force now, unlike the larger revision.

Limit on this answer. An implementing regulation binds notified bodies, not clinicians, and it does not change the substantive safety and performance requirements of MDR or IVDR. The December 2025 simplification proposal is a proposal only; nothing in it applies. The exact adoption date within May 2026 is not verified here.

Authority: Commission Implementing Regulation (EU) 2026/977 — uniform requirements for conformity assessment and notified bodies (MDR/IVDR, Annex VII), adopted May 2026 — European Commission — medical devices, new regulations (lists Implementing Regulation (EU) 2026/977 and the 16 December 2025 proposal) · European Commission — COM(2025) 1023 final (proposal text)

Verified August 17, 2026 · full entry: 2026 record

Will electronic prior authorization reach drugs?

Drug prior authorization is where most practices lose the most staff time. The proposal's usage-metric reporting is the part with teeth, because it makes plan behaviour comparable rather than anecdotal.

Limit on this answer. Proposed only; no duty arises from publication.

Authority: CMS-0062-P — Interoperability Standards and Prior Authorization for Drugs, published 14 April 2026 — CMS — CMS-0062-P proposed rule

Verified August 15, 2026 · standing record: /enforcement/#cms-0062 · full entry: 2026 record

How do I find out whether an AI device was validated on patients like mine?

The disaggregated-data expectation is the part a physician can use. A device authorised in Canada should be able to say how it performed in the populations a clinic actually serves, and the guidance makes that a documented submission element rather than a courtesy.

Limit on this answer. Guidance states current thinking and is not binding law; it imposes no new statutory obligation and may be revised. Dated April 2026 on the departmental page; the exact publication day is not verified here.

Authority: Health Canada, Pre-market guidance for machine learning-enabled medical devices (Class II–IV), April 2026 — Health Canada — Pre-market guidance for machine learning-enabled medical devices · Health Canada — guidance document (PDF)

Verified August 17, 2026 · full entry: 2026 record

Can a management company replace me as the owner of my own professional corporation?

This is the view a practice will be litigating against, and it targets a clause that appears in a great many management agreements as boilerplate succession language.

Limit on this answer. An amicus position is persuasive, not binding, and two amici disagree on the standard. The appeal was pending on the record read; no appellate ruling has issued.

Authority: Amicus curiae brief of the California Attorney General, Art Center Holdings, Inc. v. WCE CA Art, LLC, No. B338625 (Cal. Ct. App., 2d Dist., Div. Three), filed 30 March 2026 — California Attorney General — announcement of the amicus filing · California Medical Association — amicus brief, No. B338625 (filed 15 April 2026)

Verified August 17, 2026 · standing record: /enforcement/#art-center · full entry: 2026 record

Does a plan's pattern of late payment-dispute handling have consequences?

Provider dispute resolution has acknowledgment and resolution deadlines, and a plan's pattern of missing them is itself the violation — separate from whether any individual claim was payable. A practice that documents dispute dates is documenting the element the Department enforces on.

Limit on this answer. A penalty against a plan resolves no individual dispute and makes no finding about any provider's billing. The per-plan allocation of the total was not read at source.

Authority: DMHC enforcement action announced 4 February 2026; Knox-Keene Act provider dispute resolution requirements — DMHC — press releases index · DMHC — Enforcement Actions Database

Verified August 17, 2026 · full entry: 2026 record

Is a generative scribe or triage tool a regulated device?

Intended purpose is the operative concept, so a tool marketed as an assistant is regulated on what it is for, not what it is called. Where a practice deploys a generative tool for a purpose outside its registered intended purpose, the guidance's own remedy is to cease supply or revise the purpose and re-submit — which makes off-label deployment the deploying organisation's exposure.

Limit on this answer. Guidance interprets the Therapeutic Goods Act framework; it is not itself legislation. The exact date of the February 2026 update, and the listing of software as a medical device among the TGA's stated compliance priorities for 2026–2027, are not verified here.

Authority: TGA guidance, Artificial intelligence (AI) and medical device software regulation, updated February 2026 — TGA — Artificial intelligence (AI) and medical device software regulation · TGA — overview of software and artificial intelligence

Verified August 17, 2026 · full entry: 2026 record

How far ahead can I schedule telehealth with confidence?

Geographic and originating-site relief, the expanded practitioner list, audio-only coverage and the deferral of the in-person requirement for tele-behavioural care all continue — but on a date certain, not permanently. Any 2028 schedule built on them is built on an authority that expires first.

Limit on this answer. An appropriations extension is not permanence. The same provisions have now lapsed and been restored twice in four months.

Authority: H.R. 7148, Consolidated Appropriations Act, 2026 (119th Cong.), signed 3 February 2026 — Congress.gov — H.R. 7148, Consolidated Appropriations Act, 2026 · GovInfo — enrolled text of H.R. 7148

Verified August 16, 2026 · full entry: 2026 record

Is there a remedy when a plan mishandles a patient's grievance?

It is the largest California plan penalty of the year to date and it is about grievance handling, not medical necessity. Where a patient's grievance goes unanswered, the physician's clinical record is often the only contemporaneous account of the request — which is what makes the chart the evidence in a complaint case.

Limit on this answer. An administrative penalty is not a judicial finding and does not establish that any particular enrollee's care was wrongly denied.

Authority: DMHC enforcement action announced 30 January 2026; Knox-Keene Act grievance and complaint requirements — DMHC — press releases index · DMHC — Enforcement Actions Database

Verified August 17, 2026 · full entry: 2026 record

Can I still start a patient on a controlled substance by telemedicine?

The date is the whole point: this authority ends on 31 December 2026, and it is the fourth time it has been extended by temporary rule rather than replaced by a permanent framework. A practice that treats tele-prescribing of controlled substances as settled policy is scheduling into an authority with a fixed expiry and no successor in force.

Limit on this answer. A temporary rule. It changes nothing about the requirement that prescriptions issue for a legitimate medical purpose by a licensed practitioner in compliance with federal and state law, and it does not create the special registration that would replace it.

Authority: Fourth Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications, 90 FR (2025-24123), published 31 December 2025; effective 1 January 2026 through 31 December 2026 — Federal Register — Fourth Temporary Extension (31 December 2025) · HHS — announcement of the extension, 2 January 2026

Verified August 17, 2026 · full entry: 2026 record

Why did my Medicare conversion factor rise while my procedure payments fell?

A headline increase and a code-level cut arrive together, so the net effect depends entirely on a practice's mix: procedural, non-time-based work absorbs the efficiency adjustment while time-based codes do not. The APM differential also converts model participation from a bonus question into a rate question.

Limit on this answer. In force. The 2.5 percent statutory increase inside the conversion factors is a one-year addition, not a new baseline.

Authority: CY 2026 Medicare Physician Fee Schedule final rule, 90 FR (2025-19787), effective 1 January 2026 — Federal Register — CY 2026 Physician Fee Schedule final rule · CMS — Physician Fee Schedule

Verified August 16, 2026 · full entry: 2026 record

What in a management agreement now violates a California statute rather than a doctrine?

The conduct is now named in statute rather than inferred from a line of authority, and the fee award changes enforcement economics. Read a management agreement for three powers specifically: override of a clinical decision, control of billing policy, and productivity-based staffing.

Limit on this answer. In force. Enforcement to date has proceeded by settlement, so no judicial construction of the new sections exists yet.

Authority: Senate Bill 351, Ch. 409, Stats. 2025, effective 1 January 2026 — SB 351 (California Legislative Information)

Verified August 14, 2026 · standing record: /enforcement/#sb-351 · full entry: 2026 record

Does an MSO transaction need state notice now?

Deal timelines lengthen for the entities most often used to assemble physician practices, and a transaction that was structured to avoid notice may no longer avoid it.

Limit on this answer. In force. The statute is the operative authority stated here; no implementing regulation forms part of this record.

Authority: Assembly Bill 1415, Ch. 641, Stats. 2025, effective 1 January 2026 — AB 1415 (California Legislative Information)

Verified August 14, 2026 · standing record: /enforcement/#ab-1415 · full entry: 2026 record

Can a plan still deny without telling me why?

A denial without a specific reason is now a compliance failure as well as a clinical obstacle, which changes what a practice should demand in writing before starting an appeal.

Limit on this answer. In force for timeframes and denial reasons only; the API obligations are not yet due.

Authority: CMS-0057-F — Interoperability and Prior Authorization final rule — CMS — Interoperability and Prior Authorization final rule (CMS-0057-F)

Verified August 14, 2026 · standing record: /enforcement/#cms-0057-f · full entry: 2026 record

23

What can I still comment on, and what closed while I was not looking?

Two lists, and the difference between them is the whole answer. Closed: CMS-4215-P on Medicare drug-price negotiation and the two IPAY 2029 information collections closed 17 August; the Medical Board’s written-comment deadline closed 12 August, though live comment remains at the meeting. Still open: the CY 2027 Physician Fee Schedule to 14 September; CMS’s draft guidance on manufacturer effectuation of the 2028 maximum fair price to 18 September, by email rather than regulations.gov; the TGA device-information consultation to 2 October; and FDA’s generative-AI device docket, FDA-2026-N-7874, to 19 October.

Limitation. A closed comment period is not a decided rule. CMS-4215-P remains a proposal and binds no one; its comment window closing changed the window, not the rule. A comment filed is not a duty created.

Start with Medicare drug price negotiation, public participation in regulation and pre-market vs post-market surveillance.

Record: issue of 18 August 2026 · earlier state preserved in the issue of 17 August 2026

Verified August 18, 2026 · Approved for publication by Kanwar Partap Singh Gill, MD · September 5, 2026

24

What is the Medical Board of California considering on 19–21 August?

The Board’s published agenda carries its Enforcement Program Summary including the expert reviewer programme; eighteen bills, among them AB 408 on the physician health and wellness programme, four artificial-intelligence measures (AB 1979 and AB 2575 on AI in health care services, SB 903 on AI and mental-health professionals, SB 1146 on digital replicas in health advertising), SB 1002 on a telehealth licence exemption for out-of-state physicians, AB 2386 on the Licensed Physicians from Mexico Program and SB 849 on reinstatement after surrender for sexual misconduct; CME requirements under Business and Professions Code sections 2191 through 2196.9; an Interstate Medical Licensure Compact update; and a presentation on AI in health care. Panels A and B sit on 19 August; the Board meets 20–21 August in La Jolla.

Limitation. An agenda establishes what may be discussed, not what will be decided — every item is captioned “discussion and possible action.” A bill on the agenda is a bill, not law, and Board support changes no duty. Written comment closed 12 August; live comment is three minutes per item.

Start with The AB 408 post-mortem, California and the IMLC, CME vs continuing certification, telemedicine across state lines and AI in licensing and monitoring.

Record: issue of 17 August 2026

Verified August 17, 2026 · Approved for publication by Kanwar Partap Singh Gill, MD · September 5, 2026

25

What did OIG actually find about sacroiliac-joint injection billing, and what did it not find?

It found that 72 of 100 sampled sessions did not comply with Medicare requirements, and projected 134,526 of 186,842 sessions improperly paid across the year to 30 September 2024 — an estimated $15.2 million. A large share turned on therapeutic injections billed as diagnostic. It recommended contractor education and consideration of greater national consistency in local coverage rules; CMS concurred with two of three recommendations.

Limitation. It did not find fraud, name any physician, or establish a violation by any clinician. An audit finding is not an enforcement action, and the recommendations run to CMS rather than to providers. Because local coverage determinations differ between contractors, identical billing can be compliant in one jurisdiction and not in another.

Start with Interpreting enforcement statistics, why enforcement data need context and inspectors general and GAO in health oversight.

Record: issue of 17 August 2026

Verified August 17, 2026 · Approved for publication by Kanwar Partap Singh Gill, MD · September 5, 2026

26

My patient’s pharmacy refused a refill. Did something change?

From 21 August 2026 Medi-Cal Rx applies revised early-refill thresholds to members aged 21 and older. A refill is blocked where the member has not used at least 75 per cent of the previous fill of the same medication by name, strength and formulation — 90 per cent for opioids — or where cumulative early fills exceed a 20-day supply of that medication across 180 days. Claims deny with Reject Code 88, reason-for-service code ER, overutilisation. A vacation-supply override, submission clarification code 03, is available once per 365 days.

Limitation. The change alters refill timing and claim adjudication only. It does not change coverage, formulary status, quantity limits or prior-authorisation criteria for any drug, and it does not apply to members under 21. It is a point-of-sale rule, so no notice reaches the prescriber before the refusal does.

Start with Medi-Cal dental, vision, pharmacy and medical benefits, medication adherence and opioid safety.

Record: issue of 17 August 2026

Verified August 17, 2026 · Approved for publication by Kanwar Partap Singh Gill, MD · September 5, 2026

27

Did FDA just issue binding rules for generative-AI medical devices?

No. On 18 August FDA issued a discussion paper and request for feedback. It sketches a two-axis risk framework, a premarket approach built on competency assessment — non-clinical benchmarking followed by clinical confirmation, modelled at a high level on how physicians are trained and evaluated — risk-proportionate postmarket monitoring, and questions about foundation models and agentic systems. Every section asks rather than requires. Feedback goes to docket FDA-2026-N-7874 by 19 October 2026.

Limitation. Not a rule, not draft guidance, not final guidance. FDA states expressly that it is not proposing or implementing policy changes and is not communicating regulatory expectations, and the paper does not address whether the approaches discussed fall within existing legal authority. Nothing in it changes what a clinician may use today or what a manufacturer must submit.

Start with how the FDA reviews AI-enabled devices, the regulatory framework across the AI lifecycle and continuous-learning algorithms.

Record: issue of 18 August 2026 · Enforcement Watch

Verified August 18, 2026 · Approved for publication by Kanwar Partap Singh Gill, MD · standing approval of 17 August 2026, applied 18 August 2026

28

Did the Medicare drug-negotiation rule become final when comments closed on 17 August?

No. Two states move independently and only one of them moved. The comment window is closed; the instrument is still a proposed rule. Nothing was finalised on 17 August, no compliance date was set, and no duty commenced. The next event on this record is a final rule, if and when CMS issues one.

Limitation. A closed comment period is not a final rule and not an effective date. Nor does closure foreclose the proposal: it remains PROPOSED until CMS acts.

Start with Medicare drug price negotiation, statute vs regulation vs guidance and public participation in regulation.

Record: issue of 18 August 2026 · pre-closure state preserved at 17 August

Verified August 18, 2026 · Approved for publication by Kanwar Partap Singh Gill, MD · standing approval of 17 August 2026, applied 18 August 2026

29

Are the recalled BD intraosseous needle sets under a Class I recall?

Not on the record as read. What FDA has published is an early alert, dated 4 August 2026, notifying the public of a potentially high-risk device issue while it continues to review; BD announced a voluntary recall to user level on 31 July after its 30 July customer letter. FDA reports that as of 22 July BD had reported 45 serious injuries and four deaths associated with the issue. Five powered-driver needle kits are affected, from lots distributed between 30 September 2024 and 12 June 2026; the powered driver is not affected. Affected stock is to be identified and destroyed rather than returned.

Limitation. No Class I classification for this 2026 event appears in FDA’s device-recall database at the date of reading; the Class I record that exists (Z-1397-2022) is a separate 2022 BD intraosseous recall. Reported injuries and deaths are reports made to FDA, not adjudicated causation. FDA states that a needle already placed and functioning needs no further step, and that an unsuccessful intraosseous attempt does not exhaust vascular access.

Start with pre-market vs post-market surveillance, device safety oversight and reporting on device records.

Record: issue of 18 August 2026 · Enforcement Watch

Verified August 18, 2026 · Approved for publication by Kanwar Partap Singh Gill, MD · standing approval of 17 August 2026, applied 18 August 2026

30

Has the childhood immunization schedule changed?

Not by this instrument. Executive Order 14420 of 10 August 2026 recognises a set of recommendations, states that MMR should be given as three separate single-disease shots once such products are domestically available, and directs the HHS Task Force on Safer Childhood Vaccines to present plans within 90 days — by 8 November — for offering core childhood vaccines as single products. The White House fact sheet describes the recommendations as covering 11 diseases against the 18 it says CDC recommended in 2024, with the remainder moved to shared clinical decision-making.

Limitation. An order stating recommendations is not a schedule. By its own terms it amends no CDC schedule, no ACIP recommendation, no Vaccines for Children resolution and no product licence; it creates no right or benefit enforceable at law; it is subject to appropriations; and it changes no state school-entry requirement, which is state law. Separate single-disease measles, mumps and rubella products are not available to administer, so that part of the order describes an intention, not an option.

Record: issue of 19 August 2026

Verified August 19, 2026 · Approved for publication by Kanwar Partap Singh Gill, MD · standing approval of 17 August 2026, applied 19 August 2026

31

My patient has unsatisfactory immigration status. Do they lose Medi-Cal on 1 January 2027?

No. They keep Medi-Cal; what changes is the delivery system. From 1 January 2027 these members, including dual-eligible members, receive all covered services through Medi-Cal fee-for-service rather than a managed-care plan, implementing 2025 federal guidance that bars covering federally eligible emergency Medicaid services for this population through risk-based managed care. The consequence that reaches a practice is payment: a provider must be enrolled in Medi-Cal fee-for-service, approved through PAVE by that date, to be paid for treating them. Members are no longer assigned a primary care provider, and DHCS advises refilling prescriptions before the date.

Limitation. A delivery-system change is not an eligibility change, and it is not the October 2026 federal immigration-status reclassification or the January 2027 community-engagement requirement — three separate actions, each with its own record. Enhanced Care Management and Community Supports do not exist in fee-for-service; DHCS states care-management, case-management and community health worker services remain billable under existing codes, and the code lists it has promised were not published on the record read.

Record: issue of 19 August 2026

Verified August 19, 2026 · Approved for publication by Kanwar Partap Singh Gill, MD · standing approval of 17 August 2026, applied 19 August 2026

32

Does FDA have a new commissioner?

Not yet. On 19 August 2026 the President announced, on his Truth Social account, the naming of White House aide Heidi Overton to lead FDA — the office previously held by Marty Makary, who left in May 2026. The announcement was reported by RAPS Regulatory Focus; the nomination is subject to confirmation by the Senate.

Limitation. An announced nomination confers no office. It becomes a formal nomination when transmitted to the Senate and takes effect only on confirmation, and no agency decision — docket, guidance, review or enforcement action — reads differently because of it. This entry asserts nothing about the nominee’s views or prospects, and the Senate transmission was not on the congressional record read.

Record: the live desk

Verified August 19, 2026 · Approved for publication by Kanwar Partap Singh Gill, MD · standing approval of 17 August 2026, applied 19 August 2026

33

What actually happened at the August Medical Board meeting?

What the record supports: the meeting concluded 21 August. No action summary or approved minutes had been located on the record read 24 August, so every agenda item — the eighteen legislative positions, the audit response, each panel’s disciplinary matters — holds one state: disposition not yet identified in the publicly available record. The tracker populates outcomes from the official record, never from the agenda. Record

Verified August 24, 2026 · Approved for publication by Kanwar Partap Singh Gill, MD · September 5, 2026.

34

Is the Medi-Cal Rx early-refill rule now in force?

Yes. The revised thresholds for members 21 and older took effect as scheduled on 21 August 2026 and are the operating rule at the pharmacy counter. It is a claims-processing change, not a benefit cut: no drug left the formulary and no member lost coverage. Record · Ledger

Verified August 24, 2026 · Approved for publication by Kanwar Partap Singh Gill, MD · September 5, 2026.

35

What separates an FDA Early Alert from a recall?

An Early Alert is CDRH notifying the public of a potentially high-risk device issue while the agency is still collecting information — it is not a classified recall and not a finding of harm. A recall classification (Class I–III) can follow once FDA evaluates the firm’s action. The August alerts — kits containing recalled saline, monitoring software that can drop patients during updates, neonatal breathing circuits — each report no serious injuries or deaths as of their source dates, and each may still be classified later. Records

Verified August 24, 2026 · Approved for publication by Kanwar Partap Singh Gill, MD · September 5, 2026.

36

Which comment windows remain open after 21 August?

Computed from the dated record store on 24 August: EMA’s nicotine-dependence concept paper closes 30 August; the CY 2027 Physician Fee Schedule and the TGA automated-decision-making consultation both close 14 September; CMS’s maximum-fair-price effectuation draft guidance closes 18 September; the RAPID coverage-pathway notice closes 13 October; FDA’s generative-AI device docket closes 19 October; and the chronic-wounds docket runs to 26 October. The full run lives on the fixed-date table.

Verified August 24, 2026 · Approved for publication by Kanwar Partap Singh Gill, MD · September 5, 2026.